Actively Recruiting
Phase 2 Trial of Alisertib for Extensive Stage Small Cell Lung Cancer After Prior Chemotherapy and Immunotherapy
Led by Puma Biotechnology, Inc. · Updated on 2026-08-17
120
Participants Needed
30
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating alisertib monotherapy in patients with extensive stage small cell lung cancer SCLC who have experienced disease progression after treatment with one platinum-based chemotherapy and an anti-PD-L1PD-1 immunotherapy agent. This Phase 2 study aims to identify biomarker-defined subgroups that may benefit most from alisertib and to assess its effectiveness, safety, and how the drug behaves in the body. Participants will receive oral alisertib tablets in doses of 50 mg, 60 mg, or 70 mg taken twice daily on days 1 through 7 of each 21-day treatment cycle. The study includes only one treatment group receiving alisertib, with dose adjustments based on amendments. Treatment cycles will continue as defined by the study protocol. Throughout the study, participants will be monitored for tumor response including objective response rate, duration of response, disease control rate, progression-free survival, and overall survival, all within biomarker-defined subgroups and the enrolled population. Adverse events will be tracked from the first dose through 28 days after the last dose. The study duration for measuring outcomes is up to 36 months, with assessments conducted regularly during this period.
CONDITIONS
Brief Title
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Research Team
P
Puma Biotechnology, Inc. Clinical Operations Senior Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here